A planned NDA submission for seralutinib in PAH is set for September 2026, following positive FDA feedback. Worldwide rights to seralutinib were reacquired, consolidating global control and simplifying economics. Financial flexibility improved through a convertible note exchange and reverse stock split approval.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.